Posted by Michael Wonder on 17 Oct 2022
US FDA approves Menveo in a new single vial presentation to help prevent disease caused by meningococcal bacteria serogroups A, C, Y, and W
17 October 2022 - Single vial presentation option removes the need for reconstitution of Menveo before use in individuals 10 through 55 years of age.
GSK today announced that the US FDA has approved a new presentation of Menveo [Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Diptheria CRM197 Conjugate Vaccine] for individuals aged 10 to 55 years to help prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W.
